Ginkgo Bioworks Holdings (DNA) EBT Margin (2020 - 2026)

Ginkgo Bioworks Holdings has reported EBT Margin for 7 years, with the latest figure at 390.98% in Q1 2026.

• For the quarter ending Q1 2026, EBT Margin fell 17329.0% year-over-year to 390.98%; the trailing twelve-month figure through Mar 2026 stood at 211.5% (down 701.0% YoY), and the FY2025 full-year result was 184.3%, up 5684.0% from the prior year.
• EBT Margin for Q1 2026 stood at 390.98%, down from 243.72% in the prior quarter.
• The five-year high for EBT Margin was 63.76% in Q3 2024, with the low at 1009.31% in Q3 2022.
• Historically, EBT Margin has averaged 350.39% across 5 years, with a median of 253.88% in 2023.
• The largest YoY upside for EBT Margin was 89018 bps in 2022 against a maximum downside of 87709 bps in 2022.
• Ginkgo Bioworks Holdings' EBT Margin stood at 191.13% in 2022, then plunged by 219 bps to 609.67% in 2023, then soared by 60 bps to 245.99% in 2024, then rose by 1 bps to 243.72% in 2025, then tumbled by 60 bps to 390.98% in 2026.
• The last three EBT Margin figures came in at 390.98% (Q1 2026), 243.72% (Q4 2025), and 207.93% (Q3 2025), per Business Quant data.